CDH2 and Miyoshi myopathy: Genes whose methylation levels are lower in patients with MM than in those with MGUS, such as PHOX2A, CDH2, ADAMTS16, BTBD3, and IRS2, are responsible for cancer progression, and their increased expression is correlated with poor prognosis, reduced survival time, and increased frequency of metastases.